Observational studyBMC infectious diseases2026
Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to evaluate the real-world effectiveness and safety of direct-acting antiviral agents (DAAs) in patients with chronic hepatitis C (CHC) and to describe genotype distribution.
methodsPatients diagnosed with CHC and treated with DAAs between June 2016 and January 2023 were included in this single-center, retrospective observational cohort study.
resultsAmong the 402 patients initially evaluated, 233 patients with available sustained virological response at 12 weeks (SVR12) data were included in the final analysis. The median age was 53 years (range, 18–92), and 50.2% of patients were female; 208 patients (89.3%) were treatment-naïve. Among patients with a single HCV genotype, genotype 1b was the most prevalent. Genotype 3 infection was more frequently observed among individuals with a history of incarceration, alcohol use disorder, and intravenous drug use, whereas genotype 4 was more common among Syrian patients. Overall rates of rapid virological response, end-of-treatment virological response, and SVR12 were 95.6% (n = 195/204), 99.5% (n = 221/222), and 99.6% (n = 232/233), respectively. Compared with baseline, serum albumin concentrations (p = 0.030), WBC counts (p = 0.021), and PLT counts (p < 0.001) increased significantly, while serum AST (p < 0.001), ALT (p < 0.001), ALP (p = 0.011), and GGT (p < 0.001) enzyme activity levels showed significant decreases. Total bilirubin and AFP concentrations also declined significantly (both p < 0.001). Adverse events were infrequent and mild, with fatigue and pruritus (each n = 7, 3.0%) being the most commonly reported. No treatment discontinuation or treatment-related mortality was observed during follow-up.
conclusionIn this real-world cohort, DAA therapy was highly effective and well tolerated, including among vulnerable populations. The observed genotype distribution was consistent with previously reported national data and local population characteristics. These findings likely reflect migration-related epidemiological patterns and changing population dynamics rather than causal relationships. Targeted screening strategies and equitable access to DAAs remain essential for effective HCV control and reduction of its public health burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.